Terms: = Prostate cancer AND RAD21, HR21, 5885, ENSG00000164754, KIAA0078, FLJ25655, hHR21, MCD1, O60216, NXP1, HRAD21, FLJ40596, SCC1 AND Treatment
3 results:
1. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
2. Time from biopsy to radical prostatectomy by race in an equal-access healthcare system: Results from the SEARCH cohort.
Pereira V; Oyekunle T; Janes J; Amling CJ; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Klaassen Z; Freedland SJ; Vidal AC; Csizmadi I
Prostate; 2023 Aug; 83(11):1011-1019. PubMed ID: 37096737
[TBL] [Abstract] [Full Text] [Related]
3. Impact of Insurance Status on Radiation treatment Modality Selection Among Potential Candidates for prostate, Breast, or Gynecologic Brachytherapy.
Grant SR; Walker GV; Koshy M; Shaitelman SF; Klopp AH; Frank SJ; Pugh TJ; Allen PK; Mahmood U
Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):968-75. PubMed ID: 26452570
[TBL] [Abstract] [Full Text] [Related]
